Trial Profile
Safety and efficacy of palbociclib plus endocrine therapy as a forth line and beyond in patients with hormone receptor-positive HER2-negative advanced breast cancer: A retrospective study
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 13 Jun 2018
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 13 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology